56 results on '"Deheul, S."'
Search Results
2. Factors associated with the use of benzodiazepine and opioid prescription drug in the student population: a cross-sectional study.
- Author
-
Thomas C, Dondaine T, Caron C, Bastien A, Chérot N, Deheul S, Gautier S, Cottencin O, Moreau-Crépeaux S, Bordet R, and Carton L
- Subjects
- Humans, Female, Male, Cross-Sectional Studies, Young Adult, Adult, Adolescent, Substance-Related Disorders epidemiology, Surveys and Questionnaires, France epidemiology, Prescription Drug Misuse statistics & numerical data, Prescription Drugs, Attention Deficit Disorder with Hyperactivity epidemiology, Benzodiazepines adverse effects, Benzodiazepines therapeutic use, Analgesics, Opioid adverse effects, Analgesics, Opioid therapeutic use, Students psychology
- Abstract
The misuse of benzodiazepines and opioid medications is frequent in students. To improve our understanding of this behavior, we aimed to identify factors associated with separate and concomitant use of these substances. Anonymous self-reported questionnaires were e-mailed to students enrolled at a French university between March and July 2021, covering: sociodemographic characteristics, academics, psychoactive substance use, ADHD symptomatology (adulthood and childhood), and psychiatric/psychological or addiction follow-up. Factors associated with the use of benzodiazepines and opioid medications included female sex (OR = 1.41 [1.08; 1.86]) and OR = 1.38 [1.06; 1.79], respectively), older age (OR = 1.65 [1.04; 2.6] and OR = 2.17 [1.4; 3.36], respectively), current psychiatric/psychological follow-up (OR = 6.53 [5.18; 8.24] and OR= 1.5 [1.12; 2.0], respectively), ADHD symptomatology (OR= 2.33 [1.71;3.16] and OR= 1.61 [1.15; 2.24], respectively), polyconsumption (tobacco use for benzodiazepine users, OR = 1.38 [1.04; 1.82]; alcohol use OR = 1.67 [1.17; 2.39] and tobacco use OR = 1.62 [1.23; 2.14] for opioid users). These factors were even more strongly associated with the concomitant use of benzodiazepines and opioid medications: older age (OR = 3.64 [2.22; 5.99]), female sex (OR = 1.54 [1.1; 2.14]), grade repetition (OR = 1.7 [1.14; 2.54]), psychiatric/psychological follow-up (OR = 4.51 [3.35;6.06]), ADHD symptomatology (OR = 5.3 [3.69; 7.63]), polyconsumption (tobacco use OR = 2.05 [1.39; 3] and cannabis use, OR = 2.07 [1.97; 4.16]. The factors associated with the use of benzodiazepines and prescription opioids identified in this study could lead to the development of targeted prevention methods., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
3. Substance use disorder of equimolar oxygen-nitrous oxide mixture in French sickle-cell patients: results of the PHEDRE study.
- Author
-
Gérardin M, Rousselet M, Couec ML, Masseau A, Aquizerate A, Authier N, Deheul S, Roussin A, Micallef J, Djezzar S, Feuillet F, Jolliet P, Grall-Bronnec M, and Victorri-Vigneau C
- Subjects
- Humans, Analgesics therapeutic use, Nitrous Oxide therapeutic use, Nitrous Oxide adverse effects, Oxygen, Pain drug therapy, Anemia, Sickle Cell drug therapy, Substance-Related Disorders epidemiology, Substance-Related Disorders complications, Substance-Related Disorders drug therapy
- Abstract
Background: In many countries, nitrous oxide is used in a gas mixture (EMONO) for short-term analgesia. Cases of addiction, with significant misuse, have been reported in hospitalized patients. Patients suffering from sickle cell disease (SCD) could represent a high-risk population for substance use disorder (SUD) due to their significant pain crisis and repeated use of EMONO. The objective of the PHEDRE study was to assess the prevalence of SUD for EMONO in French SCD patients., Results: A total of 993 patients were included. Among 339 EMONO consumers, only 38 (11%) had a SUD, with very few criteria, corresponding mainly to a mild SUD due to a use higher than expected (in quantity or duration) and relational tensions with the care teams. Almost all patients (99.7%) were looking for an analgesic effect, but 68% of patients were also looking for other effects. The independent risks factors associated with at least one SUD criterion were: the feeling of effects different from the expected therapeutic effects of EMONO, at least one hospitalization for vaso occlusive crisis in the past 12 months and the presence of a SUD for at least one other analgesic drug., Conclusions: The use of EMONO was not problematic for the majority of patients. Manifestations of SUD that led to tensions with healthcare teams should alert and lead to an evaluation, to distinguish a true addiction from a pseudoaddiction which may be linked to an insufficient analgesic treatment related to an underestimation of pain in SCD patients., Trial Registration: Clinical Trials, NCT02580565. Registered 16 October 2015, https://clinicaltrials.gov/., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Could psychostimulant drug use among university students be related to ADHD symptoms? A preliminary study.
- Author
-
Caron C, Dondaine T, Bastien A, Chérot N, Deheul S, Gautier S, Cottencin O, Moreau-Crépeaux S, Bordet R, and Carton L
- Subjects
- Adult, Humans, Universities, Students, Attention Deficit Disorder with Hyperactivity epidemiology, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants adverse effects, Substance-Related Disorders drug therapy
- Abstract
We aimed to explore if psychostimulant use among student could be linked to attention deficit-hyperactivity disorder (ADHD) symptoms using a self-administered questionnaire sent by email to French students in 2021. Participants were asked about their psychostimulant use and the presence of ADHD symptoms using the Wender Utah Rating Scale and the Adult Self-Report Scale. Among the 4431 respondents, the prevalence of psychostimulant use was concerning and significantly associated with ADHD symptoms. This association could be related to undiagnosed ADHD or to psychobehavioral impairments induced by psychostimulant use underlining the need of ADHD screening and targeted prevention measures., Competing Interests: Declaration of Competing Interest OC: speaker or chairman at industry symposia (Janssen, Recordati, Indivior) The other authors have no competing interest to disclose., (Copyright © 2023. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
5. An overview of the use of psychoactive substances among students at the University of Lille during the COVID-19 health crisis: Results of the PETRA study.
- Author
-
Carton L, Bastien A, Chérot N, Caron C, Deheul S, Cottencin O, Gautier S, Moreau-Crépeaux S, Dondaine T, and Bordet R
- Subjects
- Humans, Analgesics, Opioid, Nitrous Oxide, Pandemics, Students, Benzodiazepines, N-Methyl-3,4-methylenedioxyamphetamine, COVID-19 epidemiology, Substance-Related Disorders epidemiology, Cocaine, Cannabis, Hallucinogens
- Abstract
Objectives: Students represent a population at risk for substance abuse. That risk may have been exacerbated by the COVID-19 pandemic. We aimed to describe substance abuse among students and to compare consumption according to the university field., Methods: A self-administered questionnaire was sent by email to all students at the University of Lille, France, between March and July 2021. This anonymous questionnaire included questions about sociodemographic characteristics, university courses and the use of psychoactive substances (frequency, reasons, routes of administration) since the first university year., Results: Among the 4431 students who responded (response rate 6.1%), eighty percent declared having used alcohol since the first university year, 34% cannabis, 15.4% benzodiazepines, 14.7% opioid drugs, 7.5% cocaine, 6.8% nitrous oxide and 6.5% MDMA. More than 20% of the users of cannabis, benzodiazepines, amphetamines and cocaine reported having already felt dependent. Recreational use was described by more than 10% of benzodiazepine or opioid drug users. Nitrous oxide use was significantly more frequent in the health and sport field ( p < 0.001). Tobacco, benzodiazepine, cannabis and MDMA uses were significantly more frequent in the humanities and social sciences/art, language and literature fields ( p < 0.001)., Conclusion: Prevention measures focusing on alcohol, cannabis, illicit psychostimulants, nitrous oxide and prescription drugs are required in the student population.
- Published
- 2023
- Full Text
- View/download PDF
6. [Nitrous oxide poisoning: Increasing consumption with serious consequences].
- Author
-
Gernez E, Deheul S, Joncquel M, Tard C, Douillard C, and Grzych G
- Subjects
- Humans, Nitrous Oxide, Drug-Related Side Effects and Adverse Reactions
- Published
- 2023
- Full Text
- View/download PDF
7. Comparison of biomarker for diagnosis of nitrous oxide abuse: challenge of cobalamin metabolic parameters, a retrospective study.
- Author
-
Grzych G, Deheul S, Gernez E, Davion JB, Dobbelaere D, Carton L, Kim I, Guichard JC, Girot M, Humbert L, Bennis A, Joncquel M, Chieux V, Joly A, Nasserdine P, Trillot N, Douillard C, Pigny P, and Tard C
- Subjects
- Humans, Vitamin B 12, Nitrous Oxide adverse effects, Retrospective Studies, Methylmalonic Acid, Biomarkers, Substance-Related Disorders complications, Vitamin B 12 Deficiency chemically induced, Vitamin B 12 Deficiency diagnosis
- Abstract
Background: Recreational use of nitrous oxide (N
2 O) leads to neurological disorders including combined subacute degeneration of spinal cord, psychological disorders, and thrombosis. Serum or urine N2 O assays could not be routinely performed. Hence, it is necessary to investigate other biological markers such as metabolic markers. We aimed here to challenge the three main biological markers used for the diagnosis of nitrous oxide abuse as total vitamin B12, homocysteine, and methylmalonic acid., Methods: We retrospectively collected clinical and biological data from 52 patients with known, documented chronic N2 O abuse and associated clinical signs (peripheral neuropathy disability score or thrombosis event). Sera and plasma total vitamin B12, methylmalonic acid (MMA), and homocysteine were performed to identify the most specific marker of chronic N2 O intoxication and related clinical outcomes., Results: Plasma homocysteine was almost consistently increased in case of N2 O chronic consumption, whereas MMA increase and total vitamin B12 decrease are not systematically found. Our results showed that none of the markers are correlated with levels of N2 O consumptions. However, homocysteine and MMA are correlated with clinical severity, but MMA seems to be a better marker of clinical severity., Conclusion: There is no specific marker of nitrous oxide abuse according to levels of consumption, total vitamin B12 decrease could not be used either as consumption or as severity marker. However, we showed that homocysteine is consistently increased and could be used as marker of recent N2 O consumption. On the other hand, we showed that MMA could be used as a marker of clinical gravity., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)- Published
- 2023
- Full Text
- View/download PDF
8. Plasma Methionine and Clinical Severity in Nitrous Oxide Consumption.
- Author
-
Gernez E, Deheul S, Tard C, Joncquel M, Douillard C, and Grzych G
- Abstract
In the last few years, there has been an increase in the recreational use of nitrous oxide (N2O), which can lead to neurological symptoms such as sensory or motor disorders. The literature links these symptoms to a functional inactivation of vitamin B12 by oxidation of its cobalt ion, which prevents the vitamin B12 from acting as a cofactor for methionine synthase. Thus, demyelination related to methionine deficiency could be responsible for the neurological disorders associated with N2O consumption, including the combined sclerosis of the spinal cord. We aimed to study the correlation between the plasma methionine levels and clinical severity observed in N2O users. We retrospectively collected clinical and biological data from 93 patients who chronically consumed N2O. The patients were divided into four groups based of the severity of their clinical symptoms (based on their Peripheral Neuropathy Disability (PND) score). The plasma amino acids measurement, including methionine, were performed systematically by liquid chromatography coupled with mass spectrometry. Plasma methionine is significantly correlated with the clinical severity (Spearman coefficient: −0.42; p-value < 10−5), however, the average methionine level in the four groups is within the physiological values (N: 16−23 µmol/L). There is a significant inverse correlation between plasma methionine and homocysteine (Spearman coefficient: −0.57; p-value < 10−9), which confirms the action of nitrous oxide on the methionine synthase. A decrease in plasma methionine cannot be imputed as the only mechanism involved in the pathophysiology of the neurological disorders in nitrous oxide consumption. In addition, there are few therapeutic indications for the use of methionine. Thus, we should be careful concerning the potential use of methionine in nitrous oxide consumption. As a consequence, other pathophysiological mechanisms probably need to be identified in order to find potential therapeutic targets.
- Published
- 2022
- Full Text
- View/download PDF
9. Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels.
- Author
-
Largeau B, Karam A, Potey C, Caous AS, Tard C, Carton L, Kuchcinski G, Gautier S, Deheul S, and Bordet R
- Subjects
- Adolescent, Adult, Ataxia, Female, Humans, Male, Nitrous Oxide adverse effects, Vitamin B 12 adverse effects, Young Adult, Nervous System Diseases, Peripheral Nervous System Diseases chemically induced, Substance-Related Disorders complications
- Abstract
Background and Purpose: Although several case series have described nitrous-oxide-associated neurological disorders, a comprehensive assessment of exposure characteristics (e.g., time to onset, level of exposure) in substance abusers has not been performed. The aim of this study was to describe the onset patterns of recreational use of nitrous-oxide-induced neurological disorders., Methods: All cases of neurological disorders related to nitrous oxide recreational use reported to the Hauts-de-France addictovigilance center between January 2019 and August 2020 were selected. Only cases requiring hospitalization with informative data to perform the nitrous oxide causality assessment were included., Results: A total of 20 cases from five hospitals were included. The male-to-female ratio was 6:1 and the median age was 19 years (range 16-34). The neurological presentation (myeloneuropathy 64%, 7/11; sensorimotor neuropathy 36%, 4/11) included for all patients gait disorders due to proprioceptive ataxia and limb hypoesthesia. The median dose used per occasion was 100 cartridges (range 5-960; n = 19). The median time from the start of nitrous oxide use to the onset of neurological symptoms was 6 months (range 0.7-54; n = 16). The cumulative dose was significantly higher in patients with damage to all four limbs than in patients with lower limb symptoms only (p = 0.042)., Conclusions: A low intermittent exposure may be sufficient to cause neurological damage in some subjects, suggesting that, at the population level, there is no safe exposure to nitrous oxide in recreational settings. The severity of neurological impairment could increase once used at high doses and for prolonged durations of nitrous oxide., (© 2022 European Academy of Neurology.)
- Published
- 2022
- Full Text
- View/download PDF
10. Biological markers and metabolic impact of chronic nitrous oxide consumption
- Author
-
Grzych G, Deheul S, Davion JB, Lemonnier F, Dobbelaere D, Carton L, Kim I, Guichard JC, Girot M, Humbert L, Joly A, Douillard C, and Tard C
- Subjects
- Biomarkers, Humans, Nitrous Oxide adverse effects, Oxygen Consumption
- Published
- 2022
- Full Text
- View/download PDF
11. Chemsex practice in France: An update in Addictovigilance data.
- Author
-
Batisse A, Eiden C, Deheul S, Monzon E, Djezzar S, and Peyrière H
- Subjects
- Adult, France epidemiology, Humans, Male, Middle Aged, Pharmacoepidemiology, Public Health, Surveys and Questionnaires, HIV Infections, Substance-Related Disorders epidemiology
- Abstract
Background: Complications related to Chemsex practice (consumption of psychoactive substances in sexual context) were first assessed by the French Addictovigilance Network in 2014. In response to the deaths reported in 2016, a new expert report was commissioned to update the complications and evolution of Chemsex-related practices in France., Methods: Between January 2008 and August 2017, all Chemsex cases collected through the French Addictovigilance Network's epidemiological tools were analyzed. Comparison of data between two periods (before and after 2014) was performed to assess the evolution of practices., Results: Over the entire survey period, 235 Chemsex cases were identified, all of them in men, with a mean ± SD age of 39 ± 11 years, including 24 deaths (10.2%). An increase in the number of reported cases was observed from one in 2008 to 50 in the first 8 months of 2017. The main medical histories include human immunodeficiency virus (HIV; 45%) and hepatitis C (20%) infections, and substance use disorders (36%). In those 235 cases, 345 psychoactive substances were identified, mainly cathinones. Polydrug use was reported in 75% of cases. The main complications were substance use disorders (63%), acute neurological or cardiovascular intoxications (50%), various psychiatric disorders (39%), and viral and bacterial infections (18%). γ-Butyrolactone (GBL) was present in 95% of comas. An increase in the number of deaths was observed during the survey period., Conclusion: The French Addictovigilance Network, via this pharmacoepidemiological surveillance, warns public health authorities in order to support harm reduction programs and the management of Chemsexers., (© 2021 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2022
- Full Text
- View/download PDF
12. Nitrous oxide abuse in the emergency practice, and Review of toxicity mechanisms and potential markers.
- Author
-
Joncquel Chevalier-Curt M, Grzych G, Tard C, Lannoy J, Deheul S, Hanafi R, Douillard C, and Vamecq J
- Abstract
Nitrous oxide (N
2 O) toxicity is a concern common to several medical fields. Here, retrospective study of four N2 O abuses with neurological signs in the emergency practice provides a preliminary basis for a metabolic Discussion/Review. This latter highlights N2 O abuse as pathology of DNA/RNA/protein methylations, for instance consistent with impairments of protein arginine methyltransferases involved in myelinogenesis and myelopathy in patients. Basically, pathogenesis starts with oxidation by N2 O of coordinated cobalamine cobalt ions at enzyme sites with impairments of vitamin-B12-dependent pathways. Methionine synthase (methylcobalamine) and methymalonyl-CoA mutase (adenosylcobalamine) are inactivated and cofactor-depleted, respectively. The number of impacted pathways (folate cycle, methylation cycle, S-adenosylmethionine-dependent methyltransferases, transulfuration pathway, Krebs cycle fueling by methylmalonyl-CoA, glutathione synthesis) explains the variety of potential research/laboratory markers, and may provide new clues and future angles to explore N2 O toxicity. Overall, homocysteine measurements obviously help diagnosis of N2 O abuses. Additional markers may include vitamin-B12, methionine, methylmalonate, dimethylglycine, sarcosine, S-adenosylmethionine to S-adenosylhomocysteine ratio, various S-adenosylamino acids, S-adenosylmethionine-dependent cellular methylations, and additional analytes (propionylcarnitine, propionylglycine, cystathionine and derived metabolites, methylated amino acids [eg arginine], betaine)., (Copyright © 2022 Elsevier Ltd. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
13. [Methylmalonic acid: Specific marker of chronic nitrous oxide abuse?]
- Author
-
Grzych G, Gernez E, Deheul S, and Kim I
- Subjects
- Humans, Nitrous Oxide adverse effects, Vitamin B 12, Methylmalonic Acid, Vitamin B 12 Deficiency
- Published
- 2022
- Full Text
- View/download PDF
14. Increase in pregabalin recreational use in adolescents in France.
- Author
-
Dufayet L, Care W, Deheul S, Laborde-Casterot H, Nisse P, Langrand J, and Vodovar D
- Subjects
- Adolescent, Adult, Age Factors, Child, Female, France epidemiology, Humans, Male, Risk Assessment, Risk Factors, Substance-Related Disorders diagnosis, Substance-Related Disorders psychology, Adolescent Behavior, Illicit Drugs, Pregabalin, Recreational Drug Use trends, Substance-Related Disorders epidemiology
- Abstract
Introduction: Misuse/abuse of pregabalin is increasing worldwide. French Poison Control Centers (PCCs) recently received several unusual calls regarding the recreational use of pregabalin in adolescents. This study aims to describe this new and specific population of pregabalin misusers., Methods: We extracted all cases of pregabalin intentional exposures reported to the French National Database of Poisonings (FNDP) from 2004 to 2020. We compared the proportion of recreational exposure to pregabalin between adolescents (10-17 years) and adults (>18 years). We reviewed all cases of pregabalin recreational exposures in adolescent in order to describe the characteristics of this population., Results: During the study period, 382 cases of acute intentional exposure to pregabalin were reported in adolescents and 1188 in adults, 94/382 (24.6%) and 43/1188 (3.6%) were pregabalin recreational use, respectively ( p < .0001). Almost all cases of pregabalin recreational use in adolescent were reported from 2018 (86/94; 91%). Most of those adolescent patients were males (male/female ratio - 5.3:1) and the median age was 15 years (range: 11-17.8). They were homeless or living in migrant shelters in most of the cases (73/90, 81%). Two-third of these exposures (62/94; 66%) involved other toxicant(s) than pregabalin. Most of the patients remains asymptomatic (10/94; 11%), or developed minor to moderate neurological symptoms (76/94; 81%). Eight developed severe symptoms (8/94; 8%) including coma (5/8) or generalized seizures (2/8). Five patients (5/8) required oro-tracheal intubation. No fatality was reported., Conclusions: We observed a sharp increase in pregabalin recreational use in adolescents in France. It should lead to prevention campaigns, targeted at the population at risk described in this study.
- Published
- 2021
- Full Text
- View/download PDF
15. Poppers Use and High Methaemoglobinaemia: 'Dangerous Liaisons'.
- Author
-
Barrangou-Poueys-Darlas M, Gerardin M, Deheul S, Istvan M, Guerlais M, Fan, Jolliet P, Dejoie T, and Victorri-Vigneau C
- Abstract
Poppers are legal and largely used in France despite severe side effects, such as methaemoglobinaemia (MetHbia). Our work aimed to assess the prevalence of poppers consumers among patients with a MetHbia higher than or equal to 5% in French university hospitals and its evolution before and after the legalization of poppers in France. We conducted a national multicentre observational retrospective study. All patients for whom at least one MetHbia measurement was performed from 2012 to 2017 in university hospitals where the French addictovigilance network (FAN) is implanted were included. For each MetHbia measurement exceeding or equal to 5%, a return to the clinical file was made by the FAN to assess poppers consumption. We calculated the prevalence of MetHbia exceeding or equal to 5% and 25% and the prevalence of poppers consumption before and after the legalization. A total of 239 (0.14%) patients had a MetHbia level exceeding or equal to 5% with 25 (10.46%) cases of poppers consumption. Poppers consumption represented 68.4% (13 out of 19) of cases with MetHbia greater than or equal to 25%. Poppers consumption among patients with MetHbia exceeding or equal to 5% increased after the legalization from 4.76% to 11.67% (prevalence ratio PR = 2.45, 95% CI = [0.98-8.37], p -value = 0.190). The proportion of patients with a MetHbia level of 25% or more increased after the legalization from 4.76% to 8.63% (PR = 1.81, 95% CI = [0.68-6.82], p -value = 0.374). The use of poppers is very frequently reported by patients with MetHbia greater than or equal to 25%.
- Published
- 2021
- Full Text
- View/download PDF
16. Warning on increased serious health complications related to non-medical use of nitrous oxide.
- Author
-
Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, and Gillet P
- Subjects
- Humans, Nitrous Oxide adverse effects
- Published
- 2021
- Full Text
- View/download PDF
17. Descriptive analysis of sickle cell patients living in France: The PHEDRE cross-sectional study.
- Author
-
Gerardin M, Rousselet M, Couec ML, Masseau A, Guerlais M, Authier N, Deheul S, Roussin A, Micallef J, Djezzar S, Feuillet F, Jolliet P, and Victorri-Vigneau C
- Subjects
- Adolescent, Adult, Aged, Anemia, Sickle Cell complications, Anemia, Sickle Cell diagnosis, Anemia, Sickle Cell psychology, Child, Child, Preschool, Cross-Sectional Studies, Drug Prescriptions statistics & numerical data, Female, France epidemiology, Humans, Male, Middle Aged, Pain diagnosis, Pain etiology, Pain Management statistics & numerical data, Pain Measurement, Quality of Life, Severity of Illness Index, Treatment Outcome, Young Adult, Analgesics therapeutic use, Anemia, Sickle Cell drug therapy, Pain drug therapy, Pain Management methods, Psychotropic Drugs therapeutic use
- Abstract
Background: Sickle cell disease (SCD) induces chronic haemolytic anaemia and intermittent vaso-occlusion that results in tissue ischaemia causing acute, severe pain episodes that can lead to frequent hospitalizations. These consequences can have repercussions on family, social, school and/or professional life. Here, we present some of the results of the PHEDRE study (Pharmacodépendance Et DREpanocytose-drug dependence and sickle-cell disease), which is the largest study of patients with SCD in France. This paper intends to describe characteristics of the French SCD population. We also aimed to assess the impact of the disease on the lives of patients using objective and subjective variables., Methods: The PHEDRE study was a national multicentric observational study. Adults, adolescents and children with a confirmed SCD diagnosis were included in the study by their referring doctor. Then, they were interviewed by phone about their socioeconomic status, about the impact of the disease on their lives and about their analgesic and psychoactive drug use., Results: The study population consisted of 872 patients (28% were minors). Seventy-two percent of adults were active, and all minors were in school. Many patients presented criteria of severe SCD. Seventy-five percent were homozygous SS, 15% were double heterozygotes SC and 8% were heterozygotes Sβthal, 87% received specific treatment, 58% were hospitalized at least once for vaso-occlusive crisis in the past 12 months, and the number of analgesic drugs taken averaged 3.8. Seventy-five percent of patients reported academic or professional consequences related to their SCD, and 52% reported social consequences., Conclusions: The impact of SCD on patients' lives can be significant, nevertheless their social integration seems to be maintained. We highlighted respect of recommendations regarding analgesic treatments and only a few patients used tobacco, alcohol or cannabis., Trial Registration: Clinical Trials, NCT02580565; https://clinicaltrials.gov/ Registered 16 October 2015., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
18. Augmentation des complications sanitaires graves lors de l’usage non-médical du protoxyde d’azote en France.
- Author
-
Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, and Gillet P
- Subjects
- France, Humans, Pharmacovigilance, Nitrous Oxide, Substance-Related Disorders
- Published
- 2021
- Full Text
- View/download PDF
19. Hair analysis can support the follow-up addiction care after acute New Psychoactive Substances intoxication: Illustration by two cases.
- Author
-
Lagoutte-Renosi J, Richeval C, Phanithavong M, Wiart JF, Castex E, Vanhoy X, Hakim F, Deheul S, Tournebize J, Allorge D, and Gaulier JM
- Subjects
- Adult, Drug-Related Side Effects and Adverse Reactions diagnosis, Follow-Up Studies, Hair chemistry, Humans, Male, Psychotropic Drugs toxicity, Substance-Related Disorders diagnosis, Drug-Related Side Effects and Adverse Reactions etiology, Hair Analysis methods, Psychotropic Drugs analysis, Substance-Related Disorders etiology
- Published
- 2021
- Full Text
- View/download PDF
20. Takotsubo cardiomyopathy as a consequence of 4-fluoroamphetamine Mono-intoxication documented by toxicological analyses.
- Author
-
Aly SM, Deheul S, Puymirat E, Richeval C, Allorge D, and Gaulier JM
- Subjects
- Adult, Amphetamine-Related Disorders diagnosis, Cardiovascular Agents therapeutic use, Humans, Male, Substance Abuse Detection, Takotsubo Cardiomyopathy diagnostic imaging, Takotsubo Cardiomyopathy drug therapy, Takotsubo Cardiomyopathy physiopathology, Treatment Outcome, Amphetamine-Related Disorders complications, Amphetamines poisoning, Central Nervous System Stimulants poisoning, Takotsubo Cardiomyopathy chemically induced, Ventricular Function, Left drug effects
- Published
- 2021
- Full Text
- View/download PDF
21. Acute Psychosis Related to Baclofen in a Patient Treated for Binge Eating Disorder Highlights the Urgent Need to Regulate Off-Label Prescriptions.
- Author
-
Ricoux O, Carton L, Ménard O, Deheul S, Gautier S, Bordet R, and Cottencin O
- Subjects
- Drug Prescriptions standards, France, Humans, Male, Middle Aged, Baclofen adverse effects, Binge-Eating Disorder drug therapy, GABA-B Receptor Agonists adverse effects, Off-Label Use legislation & jurisprudence, Psychoses, Substance-Induced etiology
- Published
- 2019
- Full Text
- View/download PDF
22. [Supervised off-label prescribing of methylphenidate in adult ADHD].
- Author
-
Carton L, Dondaine T, Deheul S, Marquié C, Brigadeau F, Amad A, Devos D, Danel T, Bordet R, Cottencin O, Gautier S, and Ménard O
- Subjects
- Adult, Central Nervous System Stimulants administration & dosage, Central Nervous System Stimulants adverse effects, Drug Prescriptions, Electrocardiography, Female, France, Humans, Male, Medication Therapy Management, Methylphenidate administration & dosage, Methylphenidate adverse effects, Neuropsychological Tests, Patient Care Team, Psychiatric Status Rating Scales, Referral and Consultation, Treatment Outcome, Attention Deficit Disorder with Hyperactivity drug therapy, Central Nervous System Stimulants therapeutic use, Methylphenidate therapeutic use, Off-Label Use
- Abstract
Objective: Off-label prescription is a common practice in psychiatry, raising health and economic concerns. Collegial consultation could allow a framed prescription of treatments that are not authorized in specific indications. Attention Deficit Hyperactivity in adult populations (ADHD) is a striking example of a pathology where off-label prescription is frequent. First considered to be a childhood disorder, the awareness of this condition in adults is increasing, leading to the development of new clinical practices and treatments. However, the adult ADHD diagnosis and its management are still emerging in France despite a high prevalence. Treatment of adult ADHD relies on methylphenidate prescription, but the initiation of this drug is not authorized in adult populations. Methylphenidate is a central nervous system stimulant that is structurally close to amphetamine and acts as a norepinephrine and dopamine reuptake inhibitor. Due to these pharmacological properties, neuropsychiatric and cardiovascular side-effects could occur. Furthermore, its addictive potential has led France to classify it as a psychoactive drug, dispensed via secured prescription. The first prescription and the one-year follow-up are restricted to neurologists, paediatrics, psychiatrists and sleep disorders specialists at hospital. The objective of this article is to propose a multidisciplinary framework for the off-label prescription of methylphenidate in adult ADHD., Methods: The Multidisciplinary Advice Consultation for Exceptional Addiction Treatments (Consultation d'Avis Multidisciplinaire de Traitements d'Exception en Addictologie CAMTEA) was first set up in Lille for the prescription of baclofen in alcohol dependence and was then extended to topiramate in binge eating disorder. This procedure has been adapted to the particularities of ADHD in adult populations, the differential diagnosis (bipolar disorder, depressive disorder, anxious disorder, personality disorder, substance use disorder) and the co-morbidities requiring a full psychiatric and neuropsychological assessment. Moreover, a particular attention has been paid to the monitoring of neuropsychiatric, cardiovascular and misuse risk because of the potential side-effects of methylphenidate., Results: The proposed prescription framework is structured into several specialized consultations. A first psychiatric evaluation aims to diagnose adult ADHD, using the French version of the Diagnostisch Interview Voor ADHD 2.0 questionnaire (DIVA 2.0), and to assess the quality of life impact with the Weiss Functional Inventory Rating Scale (WIFRS). It also searches for the presence of differential diagnosis or co-morbidities. The second appointment consists of a pharmacological evaluation that aims to search for contraindications and potential drug interaction. A neuropsychological evaluation based on standardized tests (Weschler Adulte Intelligence Scale [WAIS IV], Conner's Continuous Performance Test 3 [CPT] and the Minnesota Multiphasic Personnality Inventory [MMPI]) is also required to evaluate neurocognitive disabilities and personality features. Once the parameters of the different assessments have been collected, the synthesis is presented during a multidisciplinary meeting in order to assess the risk-benefit ratio for each patient. Several specialties are involved in this multidisciplinary meeting: psychiatry, addictology, general medicine, addictovigilance, pharmacovigilance and neuropsychology. One strategy among three possibilities can be decided: (1) contraindication to treatment with methylphenidate, (2) attention deficit disorder that does not require medication management, and (3) indication of treatment with methylphenidate with the choice of the pharmacological form (immediate or prolonged release). A biological check-up and an electrocardiogram are carried out systematically before any treatment. If the decision is made to initiate treatment, it is started at the lowest dosage and followed by a titration phase. A weekly follow-up is carried out during the titration phase in order to assess treatment efficacy and safety. After treatment stabilization, the general practitioner can carry out the renewal, and the patient will be reassessed within the framework of the multidisciplinary consultation every 3 months., Conclusion: When an off-label prescription is being considered, it must comply with the basic rules of good clinical practice, and the benefit/risk ratio should be constantly reassessed. The proposed multidisciplinary framework, adapted to the characteristics of adult ADHD and the pharmacological properties of methylphenidate, appears to be an interesting strategy to meet the requirements of the good clinical practice. The complementary assessments carried out and the collegial framework allow enhancing the patient's follow-up and minimize the drug risk, particularly in the psychiatric, addictive and cardiovascular adverse events. Finally, this framework could also help the monitoring of other off-label treatments for ADHD, such as atomoxetine or guanfacine., (Copyright © 2018 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
23. Detecting the diverted use of psychoactive drugs by adolescents and young adults: A pilot study.
- Author
-
Jouanjus E, Falcou A, Deheul S, Roussin A, and Lapeyre-Mestre M
- Subjects
- Adolescent, Adult, Age Factors, Antitussive Agents adverse effects, Codeine adverse effects, Female, France, Humans, Ketamine adverse effects, Male, Pharmacies statistics & numerical data, Pharmacovigilance, Pilot Projects, Promethazine adverse effects, Sex Factors, Substance-Related Disorders epidemiology, Substance-Related Disorders etiology, Substance-Related Disorders prevention & control, Surveys and Questionnaires statistics & numerical data, Young Adult, Antitussive Agents chemistry, Nonprescription Drugs adverse effects, Prescription Drug Diversion prevention & control, Prescription Drugs adverse effects, Psychotropic Drugs adverse effects
- Abstract
Purpose: The increasing trend of diversion of nonprescription drugs (NPDs) by adolescents or young adults is worrying. We implemented this pilot study before a national investigation to identify requests for suspected recreational use of psychoactive drugs made by young subjects to community pharmacies., Methods: Thirty-eight French community pharmacies were asked to complete questionnaire (with age, gender of subjects; name, form, quantity of drugs) for each suspect request formulated by subjects under 26. Besides, pharmacists were asked about the regulatory measures they thought useful to decrease this diverted use by young people. Nineteen pharmacies participated. The study covered from December 12, 2016 to January 23, 2017., Results: Forty-one requests mentioning 51 drugs were reported. They concerned males (85%) aged 20 years old on average, including 6 minors. The most frequent age class was that comprised between 18 and 20 years old. Codeine-containing drugs (29 reports) and promethazine (17 reports), the main components of the popular cocktail "Purple drank," were the most requested, followed by dextromethorphan (3 reports). Fifteen drugs were requested in syrup form. One request concerned the prescription drug ketamine. Pharmacists suggested to schedule the concerned NPDs to prescription-only drugs and to increase the education of students as well as the public., Conclusions: Codeine and promethazine, the main components of the popular cocktail Purple drank, were the most requested. Suspect requests of psychoactive drugs made by adolescents or young adults in community pharmacies should be carefully surveyed and combined to the monitoring of falsified prescriptions., (© 2018 John Wiley & Sons, Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
24. [Pharmaceutical cognitive doping in students: a chimeric way to get-a-head?]
- Author
-
Carton L, Cabé N, Ménard O, Deheul S, Caous AS, Devos D, Cottencin O, and Bordet R
- Subjects
- Female, Humans, Illicit Drugs, Male, Pharmacoepidemiology, Prevalence, Universities, Young Adult, Nootropic Agents, Performance-Enhancing Substances, Students
- Abstract
For students, the pressing demands for memorization, top-level performance, and peer competition create an environment favorable for pharmaceutical cognitive doping behavior. We aimed to describe recent practices and the benefit / risk ratio of such behavior and to discuss the issues at stake. The prevalence of pharmaceutical cognitive doping among students has been reported from 1.3% to 33% across studies, with variations depending on country and definition of pharmaceutical cognitive doping. The therapeutic classes most frequently cited as being diverted for doping purposes are psychostimulants and nootropics (methylphenidate, modafinil, piracetam), corticosteroids, sedative drugs and beta-blockers. Some illegal substances such as cannabis, amphetamines and cocaine are also consumed in order to boost mental function. Finally, over-the-counter products, such as caffeine-based tablets or energy drinks, or alcohol, are also widely used by students whose motivations involve enhanced performance, concentration, memory, and staying awake during the revision and exam period. However, the expected (often fantasized) effectiveness of these products does not correspond to the reality of a modest controversial impact on cognitive performance. There appears to be an emerging profile of the student more inclined to doping behavior. Cognitive doping thus raises the question of its regulation, opening a debate opposing, on one hand, individual freedom and supposed collective benefits and, on the other hand, health consequences, educational (in)equality, and the risk of tarnished academic success. Strengthening school and university medicine, through prevention campaigns and the identification of subjects at risk, is essential to limit the extent, risk, and damages associated with such practices., (Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
25. Pharmaceutical cognitive doping in students: A chimeric way to get-a-head?
- Author
-
Carton L, Cabé N, Ménard O, Deheul S, Caous AS, Devos D, Cottencin O, and Bordet R
- Subjects
- Humans, Amphetamines, Caffeine, Central Nervous System Stimulants, Cognition, Students
- Abstract
For students, the pressing demands for memorization, top-level performance, and peer competition create an environment favorable for pharmaceutical cognitive doping behavior. We aimed to describe recent practices and the benefit/risk ratio of such behavior and to discuss the issues at stake. The prevalence of pharmaceutical cognitive doping among students has been reported from 1.3% to 33% across studies, with variations depending on country and definition of pharmaceutical cognitive doping. The therapeutic classes most frequently cited as being diverted for doping purposes are psychostimulants and nootropics (methylphenidate, modafinil, piracetam), corticosteroids, sedative drugs and beta-blockers. Some illegal substances such as cannabis, amphetamines and cocaine are also consumed in order to boost mental function. Finally, over-the-counter products, such as caffeine-based tablets or energy drinks, or alcohol, are also widely used by students whose motivations involve enhanced performance, concentration, memory, and staying awake during the revision and exam period. However, the expected (often fantasized) effectiveness of these products does not correspond to the reality of a modest controversial impact on cognitive performance. There appears to be an emerging profile of the student more inclined to doping behavior. Cognitive doping thus raises the question of its regulation, opening a debate opposing, on one hand, individual freedom and supposed collective benefits and, on the other hand, health consequences, educational (in)equality, and the risk of tarnished academic success. Strengthening school and university medicine, through prevention campaigns and the identification of subjects at risk, is essential to limit the extent, risk, and damages associated with such practices., (Copyright © 2018 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
26. On-the-ground application of the 'temporary recommendation for use' regulatory measure on off-label use of baclofen for alcohol dependence in France: a regional survey of community pharmacies.
- Author
-
Auffret M, Rolland B, Caous AS, Gaboriau L, Deheul S, Bordet R, and Gautier S
- Subjects
- Alcoholism diagnosis, Alcoholism physiopathology, Alcoholism psychology, Attitude of Health Personnel, Baclofen adverse effects, Drug Prescriptions, France, GABA-B Receptor Agonists adverse effects, Government Regulation, Health Care Surveys, Health Knowledge, Attitudes, Practice, Humans, Pharmacists, Policy Making, Practice Patterns, Physicians', Professional Role, Program Evaluation, Alcoholism drug therapy, Baclofen therapeutic use, Community Pharmacy Services legislation & jurisprudence, Drug and Narcotic Control legislation & jurisprudence, GABA-B Receptor Agonists therapeutic use, Off-Label Use legislation & jurisprudence
- Abstract
The 'temporary recommendation for use' (TRU) is a French novel regulatory measure for off-label drug. The first TRU to be issued by the French drug agency (in March 2014) pertained to the off-label use of baclofen for alcohol dependence (AD). We performed a questionnaire-based survey of the on-the-ground application of the baclofen TRU among community pharmacies in northern France. A pharmacist from 70 of the 219 pharmacies contacted (response rate: 32.0%) completed the questionnaire. The mean ± standard deviation number of off-label baclofen prescriptions for AD was 2.3 ± 2.2 per pharmacy per month. 65.2% of these prescriptions were issued by primary care physicians. 65.7% of the pharmacists had never seen 'TRU' written on the prescription, and 80.3% delivered a prescription without checking whether the patient had been included by the prescriber in the TRU. The main criterion used to identify off-label prescribing was the patient's medical history (according to 74.6% of pharmacists) and the prescription of an above-threshold dose (73.1%). 87.1% of the pharmacists were aware of the baclofen TRU, and 42.9% had actually read the document. 17.9% of the pharmacists estimated that the TRU had changed their attitude to off-label baclofen prescription, and 29.9% (20 out of 67) of them wanted to be more involved in the TRU process. Community pharmacists were well informed about the off-label use of baclofen for AD and the TRU. However, a majority of baclofen prescribers did not fulfill the TRU requirements while a majority of pharmacists did not exert any control over these off-label prescriptions. In practice, in 2015 the TRU measure had thus a limited impact on both the baclofen prescribing and delivery practices., (© 2017 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2018
- Full Text
- View/download PDF
27. The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study.
- Author
-
Pignon B, Labreuche J, Auffret M, Gautier S, Deheul S, Simioni N, Cottencin O, Bordet R, Duhamel A, and Rolland B
- Subjects
- Adult, Alcohol Drinking, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Male, Middle Aged, Proportional Hazards Models, Treatment Outcome, Alcohol Deterrents administration & dosage, Alcoholism drug therapy, Baclofen administration & dosage
- Abstract
Objective: Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence., Methods: Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient-month into 3 categories (low dose: <90 mg/d, medium dose: 90-150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time-varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC., Results: One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64])., Conclusion: The relationship between dose of baclofen and favorable drinking outcome was U-shaped, that is, was increased at low and high doses compared to medium doses., (Copyright © 2017 John Wiley & Sons, Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
28. Extensive levamisole-induced vasculitis.
- Author
-
Desvignes C, Becquart C, Launay D, Terriou L, Patenotre P, Deheul S, Peytavin G, Dupin N, Delaporte E, and Staumont-Sallé D
- Abstract
Levamisole (an increasingly frequent contaminant of cocaine) can cause antineutrophil cytoplasmic antibody-associated vasculitis. Dermatologists should consider a diagnosis of cocaine/levamisole-associated cutaneous vasculopathy syndrome in cases of purpura of the ears and/or extensive retiform purpura in drug users. We report a case of particularly severe levamisole-induced necrotic purpura and immunological abnormalities in a 40-year-old woman., (© 2017 British Association of Dermatologists.)
- Published
- 2017
- Full Text
- View/download PDF
29. Authors' Reply to Alain Braillon's Comment on "Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France''.
- Author
-
Auffret M, Labreuche J, Duhamel A, Deheul S, Cottencin O, Bordet R, Gautier S, and Rolland B
- Subjects
- Adverse Drug Reaction Reporting Systems, France, Humans, Off-Label Use, Pharmacovigilance, Alcoholism, Baclofen
- Published
- 2017
- Full Text
- View/download PDF
30. Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.
- Author
-
Auffret M, Labreuche J, Duhamel A, Deheul S, Cottencin O, Bordet R, Gautier S, and Rolland B
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Baclofen administration & dosage, Databases, Factual, Female, France, GABA-B Receptor Agonists administration & dosage, GABA-B Receptor Agonists adverse effects, Humans, Male, Middle Aged, Off-Label Use, Young Adult, Adverse Drug Reaction Reporting Systems statistics & numerical data, Alcoholism drug therapy, Baclofen adverse effects, Pharmacovigilance
- Abstract
Introduction: Off-label prescribing (OLP) may raise serious safety concerns that traditional spontaneous reporting of adverse drug reactions (ADRs) may not identify in a timely manner. In France, the 'Multidisciplinary Consultation Service for Off-Label Prescribing in Addiction Medicine' (CAMTEA) is a proactive regional system established to identify ADRs associated with the OLP of baclofen for alcohol dependence., Objective: The aim was to demonstrate, using the French pharmacovigilance database (FPVD), that CAMTEA allowed for the reporting of a substantial amount of ADRs, comparable in nature to those provided via spontaneous reporting., Method: The 2012-2013 FPVD notifications associated with baclofen OLP were extracted. The ten most frequent types of ADRs among 'serious' and 'non-serious' reports were listed. The frequency of each type of ADR was compared between CAMTEA and spontaneous reporting, and the magnitudes of the differences were assessed using standardized differences., Results: A total of 428 baclofen reports (1043 ADRs) were identified, among which 221 (51.64%) originated from CAMTEA. The ten most frequent ADRs in 'serious' reports were (1) confusion (17.3%), (2) seizures (11.5%), (3) drowsiness/sedation (11.5%), (4) agitation (10.9%), (5) coma (9.6%), (6) hallucinations (7.7%), (7) falls (7.1%), (8) behavioral disorders (5.8%), (9) withdrawal syndrome (5.1%), and (10) space-time disorientation (5.1%). A standardized difference of <0.2 was identified for six out of the ten most frequent 'serious' ADRs, and eight of the ten 'non-serious' ADRs., Conclusion: A proactive regional pharmacovigilance system could collect a substantial amount of safety data on a specific OLP practice. The profile of the ADRs collected was similar to that seen in the nationwide spontaneous reporting system.
- Published
- 2017
- Full Text
- View/download PDF
31. Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol.
- Author
-
Rolland B, Auffret M, Labreuche J, Lapeyre-Mestre M, Dib M, Kemkem A, Grit I, Drelon M, Duhamel A, Cabe N, Vabret F, Guillin O, Baguet A, Masquelier C, Dervaux A, Deheul S, Bordet R, Carton L, Cottencin O, Jardri R, and Gautier S
- Subjects
- Alcohol Drinking prevention & control, Algorithms, Baclofen administration & dosage, Cohort Studies, Drug Monitoring methods, Follow-Up Studies, France, GABA-B Receptor Agonists administration & dosage, Humans, Off-Label Use, Prospective Studies, Surveys and Questionnaires, Alcoholism drug therapy, Baclofen adverse effects, GABA-B Receptor Agonists adverse effects, Telephone
- Abstract
Background: In France, baclofen is frequently used off-label for alcohol use disorder (AUD). Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs has never been properly assessed., Methods/design: BACLOPHONE is a prospective multicenter cohort study conducted in the Hauts-de-France and Normandie French regions. BACLOPHONE consists of the phone-based monitoring of 792 patients during their first year of baclofen treatment for AUD. Two initial phone interviews assess the medical history, current medications, and substance use as well as complete the alcohol use identification test (AUDIT) and severity of alcohol dependence questionnaire (SADQ). Daily alcohol use and baclofen doses are noted throughout the follow-up. For every reported AE, additional phone interviews determine the seriousness of the AE, the causality of baclofen using validated causality algorithms, and the final outcome. The main objective of the study is to determine the rate of patients who stop baclofen due to an AE during the first year of treatment., Discussion: BACLOPHONE will provide important safety data on baclofen as a complement to the forthcoming efficacy data of randomized clinical trials.
- Published
- 2017
- Full Text
- View/download PDF
32. [The current aspects of the use of ecstasy/MDMA in France].
- Author
-
Spadari M, Batisse A, Guerlais M, Boucher A, Daveluy A, Le Boisselier R, Gibaja V, Eiden C, Lepelley M, Roussin A, Deheul S, Frauger E, and Debruyne D
- Abstract
Methylenedioxymethamphetamine (MDMA), the active compound of ecstasy, has been used for several years, especially by young adults to benefit of psychostimulant properties. By raising the level of neuromodulators in the synapsis, MDMA can cause psychiatric and physical injuries. After reduced supplies in 2009 (number of ecstasy seizures equal to 10 percent of those recorded in 2002), judicial authorities now observed an increased availability (a half more part of seizures in 2012 than 2010). From its "Spontaneous Notifications" data base and "deaths in connection with the abuse of medicine and substances (DRAMES)", "observation of illegal drugs and misuse of psychotropic medications" (OPPIDUM), and "observation of drug dependencies in ambulatory medicine" (OPEMA) national inquiries, the French Addictovigilance network (CEIP-A) highlighted the increasing consumption of MDMA. The way of use appeared quite unchanged: users were mainly young men between 25 and 30 years; they favored an occasional use but mainly combined other products such as alcohol, cannabis and other stimulants. Severity of the clinical cases, based on hospital care and forensic data, could be consistent with the higher amounts of MDMA measured in pills., (Copyright © 2016 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
33. Illicit drugs or medicines taken by parachuting.
- Author
-
Daveluy A, Géniaux H, Eiden C, Boucher A, Chenaf C, Deheul S, Spadari M, Gérardin M, Miremont-Salamé G, and Haramburu F
- Subjects
- Adolescent, Adult, Drug Delivery Systems methods, Female, Humans, Male, Methadone chemistry, Middle Aged, N-Methyl-3,4-methylenedioxyamphetamine chemistry, Retrospective Studies, Young Adult, Illicit Drugs adverse effects, Illicit Drugs chemistry
- Abstract
Parachuting (also called bombing) is a method of drug delivery where illicit drugs or medicines are ingested after wrapping the substance. There are little data describing parachuting in the literature. To provide a description of this practice, all cases of parachuting reported to the national addictovigilance network up to 31 December 2014 were identified from spontaneous reports and specific surveillance programs. Cases were described according to the type of substance used, patient age and gender, type of complications, context of use and year of the event. Forty-five cases of parachute use were identified and most (n = 43) occurred after 2011. Patients were mostly men (60%), and mean age was 28.9 years. The context of use, known in 19 cases, was mostly recreational. Complications were present in 24 cases, of which eight were serious. The substance was supposed to be 3,4-methylenedioxymethamphetamine (MDMA) in the majority of cases (64.4%); research chemicals were more involved in the most recent years. The physical form was mainly granular (51.6%). The wrappers were a cigarette paper (nine cases) and in one case plastic package; in the other cases, the term of parachute was used without further details. The reason for use was not explained in the majority of cases; two patients indicated using a parachute for faster effect than with a methadone capsule. Clinicians should be aware of this delivery form as the results suggest that it is common and can involve a great variability of drugs., (© 2015 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2016
- Full Text
- View/download PDF
34. Catatonia and cannabis withdrawal: A case report.
- Author
-
Caudron M, Rolland B, Deheul S, Geoffroy PA, Thomas P, and Amad A
- Subjects
- Adult, Catatonia drug therapy, Excitatory Amino Acid Antagonists therapeutic use, Humans, Hypnotics and Sedatives therapeutic use, Lorazepam therapeutic use, Male, Marijuana Abuse drug therapy, Memantine therapeutic use, Substance Withdrawal Syndrome drug therapy, Catatonia complications, Catatonia diagnosis, Marijuana Abuse complications, Substance Withdrawal Syndrome complications, Substance Withdrawal Syndrome diagnosis
- Abstract
Background: Catatonia is a severe motor syndrome found in approximately 10% of all acute psychiatric hospital admissions. It can occur in various psychiatric diseases. The authors report the first case report of catatonia during cannabis withdrawal., Case Presentation: Mr. A, a 32-year-old man, reported to have smoked approximately 20 g of cannabis daily since the age of 11. Mr. A was incarcerated and was reported 3 weeks later to the medical department for having completely ceased talking and eating. At admission in the authors' department, the patient presented with classical catatonia symptoms (Bush-Francis Catatonia Rating Scale [BFCRS] score = 39/69). All laboratory results and brain magnetic resonance imaging (MRI) were normal. Six weeks after his admission and treatments by lorazepam and memantine, his BFCRS score was 0/69., Discussion: This single case study highlights the previously underreported emergence of physical and motor symptoms following cannabis withdrawal. Pathophysiological aspects of abrupt cannabis cessation contributing to γ-aminobutyric acid (GABA)/glutamate balance dysregulation and to catatonia are discussed.
- Published
- 2016
- Full Text
- View/download PDF
35. Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation.
- Author
-
Rolland B, Labreuche J, Duhamel A, Deheul S, Gautier S, Auffret M, Pignon B, Valin T, Bordet R, and Cottencin O
- Subjects
- Alcohol Drinking adverse effects, Alcohol Drinking epidemiology, Alcoholism epidemiology, Central Nervous System Depressants administration & dosage, Dose-Response Relationship, Drug, Ethanol administration & dosage, Female, Follow-Up Studies, Humans, Hypnotics and Sedatives administration & dosage, Hypnotics and Sedatives adverse effects, Male, Middle Aged, Multivariate Analysis, Prospective Studies, Risk, Alcohol Deterrents administration & dosage, Alcohol Deterrents adverse effects, Alcoholism drug therapy, Baclofen administration & dosage, Baclofen adverse effects
- Abstract
High-dose baclofen, i.e., 300 mg/d or more, has recently emerged as a strategy for treating alcohol dependence. The impact that the co-exposure of large amounts of alcohol and baclofen has on sedation is unclear. In a prospective cohort of 253 subjects with alcohol dependence, we collected daily alcohol and baclofen doses across the first year of baclofen treatment and the monthly maximum subjective sedation experienced by each patient (0-10 visual analog scale). For each patient-month, we determined the average weekly alcohol consumption (AWAC; standard-drinks/week) and the maximum daily dose of baclofen (DDB; mg/d). The occurrence of an episode of major sedation (EMS) during a patient-month was defined as a sedation score ≥7. The relationship between the EMS occurrence and the concurrent AWAC and DDB was investigated using a generalized estimating equation model. In total, 1528 patient-months were compiled (70 with an EMS). Univariate analyses demonstrated that the rate of patient-month to EMS increased gradually with AWAC (p<0.001), from 0.9% for AWAC=0 to 9.4% for AWAC >35. There was also a significant gradual risk for EMS associated with DDB (<0.001). Multivariate analysis demonstrated a significant interaction between DDB and AWAC on EMS risk (p=0.047). Each 20mg/d increase in DDB was associated with an OR of EMS in AWAC >35 of 1.22 (95%CI, 1.08-1.38) versus 1.11 (95%CI, 0.96-1.29) in AWAC=1-35, and 0.95 (95%CI, 0.76-1.19) in AWAC=0. The level of sedation observed in patients using baclofen for alcohol dependence appears to directly depend on the immediate doses of both the baclofen and the alcohol., (Copyright © 2015 Elsevier B.V. and ECNP. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
36. Dependence on Internet-Purchased Ethylphenidate.
- Author
-
Pignon B, Muyssen A, Deheul S, Cottencin O, and Rolland B
- Subjects
- Humans, Male, Methylphenidate adverse effects, Methylphenidate economics, Substance-Related Disorders economics, Young Adult, Internet economics, Methylphenidate analogs & derivatives, Substance-Related Disorders diagnosis
- Published
- 2015
- Full Text
- View/download PDF
37. Attitudes of community pharmacists to off-label prescribing of baclofen in Northern France.
- Author
-
Auffret M, Rolland B, Caous AS, Deheul S, Béné J, Cottencin O, Bordet R, and Gautier S
- Subjects
- Alcoholism epidemiology, France epidemiology, GABA-B Receptor Agonists therapeutic use, Humans, Surveys and Questionnaires, Alcoholism drug therapy, Attitude of Health Personnel, Baclofen therapeutic use, Community Pharmacy Services, Off-Label Use, Pharmacists psychology
- Abstract
Background: Community pharmacists' liability is involved when they dispense off-label prescriptions (OLPs). However, their attitudes to off-label prescribing are little known, while in France off-label baclofen use for alcohol dependence is increasing., Objective: To determine community pharmacists' attitudes to off-label prescribing of baclofen., Method: A postal questionnaire was sent to 219 community pharmacies in the Nord-Pas-de-Calais region, France, previously identified as delivering at least five boxes of oral baclofen monthly. The questionnaire examined whether pharmacists delivered baclofen for alcohol dependence, how pharmacists detected off-label prescribing of baclofen, who were the most frequent prescribers (general practitioners or specialists), and pharmacists' attitudes to OLPs., Results: Eighty pharmacies responded (36.5 %). Detection criteria for OLPs were supra-threshold dose (77.3 %) and "off-label" written on prescription (52.5 %). General practitioners were the most frequent prescribers of off-label baclofen. Pharmacists were more likely to refuse to fill prescriptions not marked "off-label" (6.0 %) than correctly marked prescriptions (1.5 %). 85 % of respondents considered they lacked information on off-label use., Conclusion: Although community pharmacists felt they were poorly informed on off-label baclofen, the majority nevertheless delivered the drug. Since our survey, off-label baclofen prescribing has been strictly controlled in France. Pharmacists' current attitudes will need further evaluation.
- Published
- 2015
- Full Text
- View/download PDF
38. New synthetic drugs in addictovigilance.
- Author
-
Chavant F, Boucher A, Le Boisselier R, Deheul S, and Debruyne D
- Subjects
- Designer Drugs chemistry, Designer Drugs pharmacology, European Union, Humans, Illicit Drugs chemistry, Illicit Drugs pharmacology, Pharmacovigilance, Psychotropic Drugs chemistry, Psychotropic Drugs pharmacology, Designer Drugs adverse effects, Illicit Drugs adverse effects, Psychotropic Drugs adverse effects, Substance-Related Disorders epidemiology
- Abstract
New substances, also known as "designer drugs" or "legal highs" are increasingly available to drug users. Two hundred and fifteen hitherto unlisted substances have been notified by European Union member states since 2005. These synthetic drugs, which have been developed to side-step the legislation on drugs, are analogues or derivatives of existing drugs and medications. The availability of these "legal highs", sold on Internet under various denominations such as bath salt, plant fertilizer, chemical not intended for human use, or spice, is unlimited. The effects felt by users vary, and the substances may be stimulant, entactogenic, hallucinogenic, psychedelic or dissociative. The pharmacological targets also vary, and may be either the increase of extracellular levels of neurotransmitters via different mechanisms (reuptake inhibition, stimulation of intracellular release) or else fixation on specific receptors. Several chemical classes, themselves divided into sub-classes, are involved: phenethylamines, tryptamines, piperazines, cathinones, cannabinoids etc. The toxicity of the main members of these categories is increasingly well known, the most deleterious being behavioural effects, physical manifestations, and cardiovascular consequences. However, small variations in their chemical structure can generate effects that are quantitatively different, thus enhancing their toxicity or addictive potential, and much remains to be achieved in terms of knowledge about these new drugs. These substances are indeed present on the French territory, as shown by data provided by the Observatoire Français des Drogues et Toxicomanies, and notifications by the French Addictovigilance network. Screening in clinical toxicology laboratories is not widespread, since these molecules are not detected by the standard screening tests, so that there is probably an under-estimation of the use of these new drugs. The legislation on these substances changes regularly, with more and more countries classifying them as "narcotics" or illegal psychotropic drugs so as to restrict their use, applying a generic classification when possible., (© 2015 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2015
- Full Text
- View/download PDF
39. [Temporary recommendation for use on off-label baclofen: viewpoint of Prescribers of the CAMTEA system].
- Author
-
Rolland B, Deheul S, Danel T, Bence C, Blanquart MC, Bonord A, Semal R, Briand T, Sochala M, Dubocage C, Dupriez F, Duquesne D, Gibour B, Loosfeld X, Henebelle D, Henon M, Vernalde E, Matton C, Bacquet JE, Molmy L, Sarasy F, Simioni N, Richez C, Gentil-Spinosi L, Vosgien V, Yguel J, Ledent T, Auffret M, Wilquin M, Ziolkowski D, Sochala M, Gautier S, Bordet R, and Cottencin O
- Subjects
- Baclofen administration & dosage, Dose-Response Relationship, Drug, France, Humans, Alcoholism drug therapy, Baclofen therapeutic use, Off-Label Use, Practice Patterns, Physicians' statistics & numerical data
- Abstract
The use of high dose baclofen for alcohol-dependence emerged in France from 2008 based on empirical findings, and is still off-label. However, due to the rapid increase in this prescribing practice, the French health authorities have decided to frame it using an extraordinary regulatory measure named "temporary recommendation for use" (TRU). Baclofen prescribers from CAMTEA, a regional team-based off-label system for supervising baclofen prescribing, which was developed much prior to the TRU, discuss herein the pros and cons of this measure and the applicability of its different aspects in the daily clinical practice., (© 2014 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2015
- Full Text
- View/download PDF
40. Safety and drinking outcomes among patients with comorbid alcohol dependence and borderline personality disorder treated with high-dose baclofen: a comparative cohort study.
- Author
-
Rolland B, Valin T, Langlois C, Auffret M, Gautier S, Deheul S, Danel T, Bordet R, and Cottencin O
- Subjects
- Adult, Alcoholism diagnosis, Alcoholism epidemiology, Alcoholism psychology, Baclofen adverse effects, Borderline Personality Disorder diagnosis, Borderline Personality Disorder epidemiology, Case-Control Studies, Comorbidity, Female, France epidemiology, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Recurrence, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Alcohol Abstinence, Alcohol Drinking prevention & control, Alcoholism surgery, Baclofen administration & dosage, Borderline Personality Disorder psychology, Off-Label Use
- Abstract
In France, the off-label use of high-dose baclofen (HDB) for alcohol dependence is spreading. HDB induces frequent neuropsychiatric adverse events (AEs). Borderline personality disorder (BPD) is a major axis-two psychiatric disorder that exposes to frequent comorbid alcohol dependence and increased risky behaviors. We investigated the drinking and safety outcomes of patients with BPD treated with HDB for comorbid alcohol dependence. In a prospective cohort of 204 patients with alcohol dependence treated by HDB, 23 patients fulfilled the Diagnostic and Statistical Manual of Mental Disorders, 4th ed. criteria for BPD. We paired two control participants without a psychiatric history with each BPD patient according to age and sex. We compared the average lengths of follow-up, average doses of baclofen received, rates of heavy drinking days, rates of serious AEs, and rates of AEs resulting in baclofen withdrawal. Between BPD patients (n=23) and controls (n=46), there were no significant differences in mean age (45.3±11.2 vs. 45.2±11.2 years), sex ratio (43.5% women), mean duration of follow-up (8.0±4.0 vs. 7.7±4.2 months; P=0.77), and average daily dose of baclofen (102.2±42.7 vs. 94.6±9.7 mg/day; P=0.44). However, the mean rate of heavy drinking days (74.3±25.3 vs. 41.7±33.3%; P<10E-4), the rate of serious AEs (65.2 vs. 6.5%; P<10E-4), and the rate of treatment discontinuation after AEs (52.2 vs. 8.6%; P<10E-4) were significantly higher in BPD. The benefit/risk balance of HDB appears to be unfavorable in comorbid BPD patients compared with nonpsychiatric patients.
- Published
- 2015
- Full Text
- View/download PDF
41. Baclofen-induced manic symptoms: case report and systematic review.
- Author
-
Geoffroy PA, Auffret M, Deheul S, Bordet R, Cottencin O, and Rolland B
- Subjects
- Alcoholism drug therapy, Baclofen therapeutic use, Humans, Male, Middle Aged, Baclofen adverse effects, Bipolar Disorder chemically induced, GABA-B Receptor Agonists adverse effects
- Abstract
Background: The gamma-aminobutyric acid type B receptor agonist baclofen is approved for spasticity and is used off-label for diverse types of addictive disorders, notably alcohol dependence. Baclofen may induce numerous neuropsychiatric adverse drug reactions, including behavioral disinhibition. However, this precise adverse drug reaction has never been assessed using either a validated causality algorithm or a scale for manic symptoms., Methods: We report a case of a 49-year-old male patient who exhibited de novo mania during treatment with baclofen for alcohol dependence. Symptoms were evaluated using the Young Mania Rating Scale, and the causality of baclofen was determined using the Naranjo algorithm. This case was also compared with other cases of baclofen-induced mania through a systematic literature review., Results: Mr. X, taking 180 mg/d of baclofen, presented with mania and scored 24 of 44 on the Young Mania Rating Scale, and the imputability of baclofen was "probable" using the Naranjo algorithm (8 of 13). In addition, 4 other cases of baclofen-induced mania were reported in the literature; 3 cases had a bipolar I disorder history. Baclofen-induced manic symptoms occurred mostly during the dose-escalation phase., Conclusion: Baclofen-induced manic symptoms may appear in patients with or without bipolar disorder. Particular attention is required during the dose-increase phase and in patients with a history of mood disorders., (Copyright © 2014 Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
42. [Iatrogenic dependence to meperidine in the elderly].
- Author
-
Rolland B, Bera-Louville A, Deheul S, Roche J, Blond S, and Cottencin O
- Subjects
- Administration, Oral, Aged, Buprenorphine administration & dosage, Dose-Response Relationship, Drug, Female, Humans, Injections, Intramuscular, Long-Term Care, Opioid-Related Disorders rehabilitation, Patient Admission, Analgesics, Opioid, Arthroplasty, Replacement, Hip, Chronic Pain drug therapy, Iatrogenic Disease, Meperidine, Opioid-Related Disorders etiology, Pain, Postoperative drug therapy
- Published
- 2014
- Full Text
- View/download PDF
43. Severe tinnitus induced by off-label baclofen.
- Author
-
Auffret M, Rolland B, Deheul S, Loche V, Hennaux C, Cottencin O, Bordet R, and Gautier S
- Subjects
- Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Off-Label Use, Alcoholism drug therapy, Baclofen adverse effects, GABA-B Receptor Agonists adverse effects, Muscle Relaxants, Central adverse effects, Tinnitus chemically induced
- Abstract
Objective: The γ-aminobutyric acid type B (GABA-B) receptor agonist baclofen is approved for spasticity up to the dose of 80 mg/d. Recently, off-label use of high-dose baclofen (HDB), up to 400 mg/d, has been increasing for treating alcohol use disorders (AUDs), although the efficacy and safety profiles of HDB are relatively unknown. We report 2 cases of tinnitus in patients treated with HDB for AUD., Case Summaries: The first case concerns a 60-year-old man who reported tinnitus when he reached a 180 mg/d dose of baclofen after 3 months of treatment. Tinnitus persisted until the dose was reduced to 90 mg/d. The second case concerns a 45-year-old woman who presented with tinnitus when she reached a 210 mg/d dose of baclofen after 4 months of treatment. Tinnitus persisted until the dose was reduced to 60 mg/d., Discussion: Using the Naranjo scale, imputability to baclofen was considered probable in both cases. GABA-B receptors have been reported to be implicated in both the etiology and the treatment of tinnitus. There may be an individual susceptibility to develop tinnitus under baclofen therapy because of some GABA-B genetic polymorphisms that remain to be determined., Conclusion: HDB may be responsible for the occurrence of severe tinnitus, possibly in a dose-dependent manner. This appears to be coherent with the previously known involvement of GABA-B receptors in the pathophysiology of tinnitus.
- Published
- 2014
- Full Text
- View/download PDF
44. Baclofen-induced edema in alcohol use disorders.
- Author
-
Bence C, Cottencin O, Deheul S, Gautier S, Bordet R, and Rolland B
- Subjects
- Adult, Ankle, Female, Humans, Male, Middle Aged, Alcohol-Related Disorders drug therapy, Baclofen adverse effects, Edema chemically induced, GABA-B Receptor Agonists adverse effects
- Published
- 2014
- Full Text
- View/download PDF
45. [Baclofen and liver cirrhosis: literature review and safety precautions implemented within the system CAMTEA].
- Author
-
Rolland B, Deheul S, Louvet A, Gautier S, Cottencin O, and Bordet R
- Subjects
- Alcoholism complications, Baclofen administration & dosage, Dose-Response Relationship, Drug, France, GABA-B Receptor Agonists administration & dosage, Gastrointestinal Diseases chemically induced, Hepatic Encephalopathy chemically induced, Humans, Interdisciplinary Communication, Referral and Consultation legislation & jurisprudence, Referral and Consultation organization & administration, Alcoholism drug therapy, Baclofen adverse effects, GABA-B Receptor Agonists adverse effects, Liver Cirrhosis chemically induced, Off-Label Use, Pharmacovigilance
- Abstract
The off-label prescribing of high dose baclofen (HDB) has been recently spreading in France. The impact of HDB on subjects with liver cirrhosis remains poorly known. The main pharmacodynamic and pharmacokinetic data on baclofen result from studies on healthy subjects or using low doses of treatment. The specific biodisponibility and elimination of HDB have not been studied yet in cirrhosis. National pharmacovigilance reports suggest that a careful use of baclofen or even HDB could be possible in compensated cirrhosis. However, theoretical risks of baclofen overdose exist in cases of hepatorenal syndrome or portosystemic shunt. Baclofen could also induce a specific pharmacological potentiation of hepatic encephalopathy and gastropathy. Within CAMTEA, a regional team-based multidisciplinary system for delivering and monitoring off-label medications in alcohol use disorders, a set of predefined precautions for using baclofen in cirrhosis have been implemented, until further information becomes available. These precautions notably consist of a protocolized process for declaring adverse events, and a hepatologic follow-up associated with the usual multidisciplinary care system set up within CAMTEA., (© 2014 Société Française de Pharmacologie et de Thérapeutique.)
- Published
- 2014
- Full Text
- View/download PDF
46. Assessing alcohol versus baclofen withdrawal syndrome in patients treated with baclofen for alcohol use disorder.
- Author
-
Rolland B, Jaillette E, Carton L, Bence C, Deheul S, Saulnier F, Bordet R, and Cottencin O
- Subjects
- Adult, Alcohol Withdrawal Delirium diagnosis, Alcohol Withdrawal Delirium etiology, Alcohol Withdrawal Delirium psychology, Alcoholism diagnosis, Alcoholism psychology, Confusion chemically induced, Delirium chemically induced, Diagnosis, Differential, Humans, Male, Middle Aged, Off-Label Use, Predictive Value of Tests, Risk Factors, Substance Withdrawal Syndrome diagnosis, Substance Withdrawal Syndrome psychology, Alcohol Abstinence, Alcohol Drinking prevention & control, Alcohol Withdrawal Delirium drug therapy, Alcoholism therapy, Baclofen adverse effects, GABA-B Receptor Agonists adverse effects, Substance Withdrawal Syndrome drug therapy, Substance Withdrawal Syndrome etiology
- Abstract
Baclofen is a γ-aminobutyric acid B (GABA-B) receptor agonist that is approved for spasticity. Recently, the off-label use of baclofen for alcohol use disorder (AUD) has increased. However, baclofen is known to induce a neuroadaptation process, which may be identified by the occurrence of a specific baclofen withdrawal syndrome (BWS), that is, confusion, agitation, seizures, and delirium. The same set of symptoms characterizes alcohol withdrawal syndrome (AWS), which could lead to mistaking BWS for AWS in some situations. We report the cases of 3 patients under a chronic baclofen treatment for AUD. The patients emergently presented with a clinical state of confusion that was initially diagnosed and treated as AWS, with limited effect of benzodiazepines. Retrospectively, using a validated algorithm for assessing drug-induced withdrawal, we determined that all of these clinical cases were consistent with BWS. Both AWS and BWS should be considered in the case of acute confusion or delirium occurring in patients treated with baclofen for AUD. Moreover, further research should investigate to what extent GABA-A and GABA-B induce shared or distinct neuroadaptation processes and withdrawal syndromes.
- Published
- 2014
- Full Text
- View/download PDF
47. [Involvement of pharmacists in systems for supervising off-label medications: example of the CAMTEA system for the prescription of baclofen in alcohol use disorder in Northern France].
- Author
-
Auffret M, Rolland B, Deheul S, Lecomte L, Cottencin O, Bordet R, and Gautier S
- Subjects
- Directive Counseling, Feasibility Studies, France, Humans, Patient Acceptance of Health Care, Pharmacists, Professional Role, Surveys and Questionnaires, Alcoholism drug therapy, Baclofen therapeutic use, Off-Label Use legislation & jurisprudence, Off-Label Use statistics & numerical data, Pharmacovigilance
- Abstract
Off-label prescribing matches the using of medications outside the summary of product characteristics. Adverse drug reactions are often poorly studied in off-label situations, which may expose patients to additional safety risks, and impose taking specific precautions. The current off-label prescribing practice of baclofen for alcohol-dependence in France is a typical illustration of such a situation. CAMTEA is a regional system set up in 2010 in Northern France, which gathers addiction and pharmacovigilance specialists, and aims at strengthening the prescription supervising and the monitoring of some off-label medication used for addictive disorders, especially baclofen. Until now, institution or office-based pharmacists have not been implicated, whereas they engaged their liability when delivering off-labeled treatment and they may highly contribute to the patient monitoring and the spotting of adverse events. We propose hereby possible measures for involving pharmacists into the patient supervising system developed within CAMTEA. In the current French context concerning the off-label use of baclofen, which will be the first off-label prescribing practice to be framed by a new legal disposition called "temporary use recommendation", the key role of pharmacists should be highlighted., (Copyright © 2013 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
48. Comment on: "Management of alcohol dependence in patients with liver disease".
- Author
-
Rolland B, Deheul S, Louvet A, Cottencin O, and Bordet R
- Subjects
- Humans, Alcohol Drinking prevention & control, Alcoholism rehabilitation, Liver Diseases, Alcoholic physiopathology
- Published
- 2013
- Full Text
- View/download PDF
49. Baclofen for alcohol-dependence: anticraving or partial substitution?
- Author
-
Rolland B, Bordet R, Deheul S, and Cottencin O
- Subjects
- Female, Humans, Male, Alcoholism drug therapy, Baclofen therapeutic use, GABA-B Receptor Agonists therapeutic use
- Published
- 2013
- Full Text
- View/download PDF
50. Belgian patients with alcohol problems are crossing the border in search of baclofen prescriptions.
- Author
-
Rolland B, Deheul S, and Cottencin O
- Subjects
- Alcoholism epidemiology, Belgium epidemiology, Humans, Prevalence, Substance Withdrawal Syndrome epidemiology, Alcoholism drug therapy, Baclofen therapeutic use, GABA-B Receptor Agonists therapeutic use, Prescription Drugs, Substance Withdrawal Syndrome prevention & control
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.